← Back to Clinical Trials
Recruiting NCT06305663

NCT06305663 A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06305663
Status Recruiting
Phase
Sponsor Bausch & Lomb Incorporated
Condition Myopia
Study Type INTERVENTIONAL
Enrollment 418 participants
Start Date 2024-03-29
Primary Completion 2027-01-31

Eligibility & Interventions

Sex All sexes
Min Age 8 Years
Max Age 12 Years
Study Type INTERVENTIONAL
Interventions
Bausch + Lomb (kalifilcon A) Myopia Control Soft (Hydrophilic)CooperVision MiSight (omafilcon A/60%) Myopia Control one day Soft Contact Lens

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 418 participants in total. It began in 2024-03-29 with a primary completion date of 2027-01-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

A Study to Evaluate the Safety and Efficacy of the Bausch + Lomb Myopia Control Lens for the Correction of Myopic Ametropia and Slowing the Progression of Myopia in Children

Eligibility Criteria

Inclusion Criteria: 1. Male or female aged 8 to 12 years plus 11 months old on the date the Informed Assent and Parental or Guardian Informed Consent are signed and have capacity to provide voluntary informed consent. 2. Subject must meet the following determined by cycloplegic subjective refraction in both eyes at screening: 1. Spherical Equivalent Refractive Error (SERE): between -0.75 D and -4.00 D, inclusive. 2. Astigmatism: ≤ -0.75 D. c. Anisometropia: \< 1.00 D. 3. Subject must be myopic and require lens correction from -0.75 D to -4.00 D, at screening, in each eye. 4. Subject must have distance best-spectacle corrected visual acuity (BSCVA) by non-cycloplegic manifest refraction of +0.04 logMAR (20/20 Snellen equivalent) or better in each eye. 5. Subject and Parent or Guardian must be willing to participate in either the test or the comparator assignment. 6. Subject agrees to wear the assigned contact lenses for a minimum of 10 hours per day, at least 6 days per week, for the duration of the 24-month study. 7. Subject must have wearable and visually functioning eyeglasses. 8. Subject must be in good general health according to their and parent's or guardian's knowledge Exclusion Criteria: 1. Subject has previously worn, or currently wears rigid gas permeable contact lenses, including orthokeratology lenses. 2. Current or prior use of bifocals, progressive addition lenses, multifocal soft contact lenses, atropine, pirenzepine or ANY other myopia control treatment. 3. Subject appears to exhibit poor personal hygiene (that in the Investigator's opinion might prevent safe contact lens wear). 4. Per oral inquiry from parents/guardian, the subject was born earlier than 30 weeks or weighed less than 1,500 g at birth. 5. Prior strabismus, intraocular, or refractive surgery. 6. Subject using any systemic or local eye medication that interfere with the wearing of corneal contact lenses, pupil size, adjustment or refractive status, or require the removal of lenses during the day". 7. A known allergy to fluorescein, benoxinate, proparacaine, or cyclopentolate. 8. A history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, ocular viral or fungal infections or other recurrent ocular infections. 9. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction. 10. Known ocular or systemic disease such as, but not limited to: anterior uveitis or iritis, episcleritis or scleritis, glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, or diabetes. 11. At the discretion of the Investigator, any ocular, systemic or neuro developmental conditions that could influence refractive development such as, but not limited to: persistent pupillary membrane, vitreous hemorrhage, cataract, corneal scarring, ptosis, eyelid hemangiomas, Marfan's syndrome, Down syndrome, Ehlers-Danlos syndrome, Stickler syndrome, ocular albinism, retinopathy of prematurity. Subjects with trichiasis, that in the Investigator's judgement does not interfere with contact lens wear, are eligible for this study. 12. Keratoconus or an irregular cornea. 13. Subjects with any Grade 2 or greater finding during the slit lamp examination, or subjects with any scar or neovascularization within the central 6 mm of the cornea, or subjects with corneal infiltrates, of ANY GRADE. 14. Subjects with any "present" finding during the slit lamp examination (biomicroscopy) that, in the investigator's judgment, interferes with contact lens wear. Subjects with minor peripheral corneal scarring (that does not extend into the central area), that in the Investigator's judgment does not interfere with contact lens wear, are eligible for this study. 15. The Investigator for any reason considers that it is not in the best interest of the Subject to participate in the study. 16. Subjects participating in any drug clinical investigation within 4 weeks or device clinical investigation within 2 weeks prior to entry into this study (Screening/Dispensing Visit) and/or planning to do so during the period of study participation. 17. Immediate family or close relative is a member of site study team members

Contact & Investigator

Central Contact

Yan Zhang

✉ Yan.Zhang1@bausch.com

📞 +86 21 60327166

Frequently Asked Questions

Who can join the NCT06305663 clinical trial?

This trial is open to participants of all sexes, aged 8 Years or older, up to 12 Years, studying Myopia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06305663 currently recruiting?

Yes, NCT06305663 is actively recruiting participants. Contact the research team at Yan.Zhang1@bausch.com for enrollment information.

Where is the NCT06305663 trial being conducted?

This trial is being conducted at Beijing, China, Dongcheng, China, Xiamen, China, Haikou, China and 7 additional locations.

Who is sponsoring the NCT06305663 clinical trial?

NCT06305663 is sponsored by Bausch & Lomb Incorporated. The trial plans to enroll 418 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: September 2026  ·  Data Methodology